Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial.
Saved in:
| Title: | Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial. |
|---|---|
| Authors: | Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA. jsheier@eyeboston.com., Zhang X; Bayer Consumer Care AG, Basel, Switzerland., Reed K; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Berliner A; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Leal S; Bayer Consumer Care AG, Basel, Switzerland. |
| Source: | Eye (London, England) [Eye (Lond)] 2025 Jan 13. Date of Electronic Publication: 2025 Jan 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
